Navigation Links
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:3/18/2008

HORSHAM, Pa. and KENILWORTH, N.J., March 18 /PRNewswire/ -- Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that a Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMEA) requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The initial submission and Phase 3 development programs are unprecedented among anti-tumor necrosis factor (TNF)- alpha therapies, as they mark the first time that an MAA has been proposed for review inclusive of three unique disease states. Golimumab, Centocor's and Schering-Plough's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four week subcutaneous injection and an intravenous (IV) infusion therapy. Pending regulatory approval in the European Union, Schering-Plough Corporation (NYSE: SGP) will assume exclusive marketing rights for golimumab in Europe.

"We look forward to working with the EMEA so that patients and physicians might one day have the opportunity to experience golimumab as a therapeutic option for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis," said Jerome A. Boscia, M.D., senior vice president, Clinical Research and Development, Centocor, Inc. "We remain focused and on track for global regulatory submissions for golimumab targeted for the first half of 2008."

Phase 3 primary endpoint study findings from the Golimumab - A
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
2. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
3. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
4. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
5. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
6. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
7. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
10. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
11. Schering-Plough Completes Acquisition of Organon BioSciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... EPFL and the University of  Geneva  (UNIGE) ... P. Donoghue . The American neuroscientist is to head ... The new Wyss Center for Bio- and Neuro-Engineering, ... , has named as its director one of the ... founder of Brown University,s Institute for Brain Science, has ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of ... to announce the relaunch of his highly informative blog, now ... called “ What are Stem Cells ?” Dr. Harman’s ... foundation in the basics of stem cell therapy so that ... type of treatment when considering regenerative medicine. , A veterinarian ...
(Date:7/10/2014)... 10, 2014 On July 9 ... , presented Russia,s first national ... The Company is developing a unique project called ... develops a number of innovative drugs based on monoclonal ... ceremony took place at the International Exhibition "Innoprom 2014" ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... Executive Chairman and CFO Assume Leadership Responsibilities; CEO Search ... ... Calif., Jan. 30 Genelabs,Technologies, Inc. (Nasdaq: GNLB ) announced ... Officer and Director of the,company, effective January 29, 2008. Irene A. ...
... BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864), ... BioPharma Corp.,announces that at the Company,s Annual General ... of the resolutions presented by,management, appointing KPMG LLP ... Jack Kay, Slawomir Majewski, and Gordon Lickrish as,directors, ...
... Fla., Jan. 30 John Wagner, M.D., recognized as,a ... transplantation, has joined,the team at CORD:USE Cord Blood Bank. ... stem cell biology will provide a,significant contribution to CORD:USE., ... a member of our,distinguished team," says Edward Guindi, M.D., ...
Cached Biology Technology:Genelabs Technologies, Inc. Announces Resignation of President and CEO 2Helix BioPharma shareholders vote in favour of management 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 3
(Date:7/11/2014)... division of the striatum is also involved in ... of substance P in the striatal marginal division ... his team, College of Biophotonics, South China Normal ... P receptor, neurokinin 1 was highly expressed in ... rats. Unilateral or bilateral injection of an antisense ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... The International Rett Syndrome Foundation (IRSF) has named ... the 7th World Congress for Rett Syndrome. ... meetings targeting researchers, clinicians, medical professionals and families ... Family Education Conference and a Science Symposium co-chaired ...
... Conservation Science and the Department of Fish and Game have ... on bird species of greatest concern. This first-of-its-kind study prioritizes ... conservation measures in California. The study was published this week ... exciting about the study is that our unique approach is ...
... thousands of cargo containers from around the world pass through ... some that are not so welcome: drugs, explosives, chemical, biological, ... The possible concealment of such items in containers led lawmakers ... cargo containersthousands per port per day. The Department of ...
Cached Biology News:New study will help protect vulnerable birds from impacts of climate change 2When your ship comes in 2When your ship comes in 3
... products ATP-Free using Mo Bio luciferase assay. Mo ... service that will allow you to certify your ... and enable you to deliver them to your ... ATP detection limit is 3.5 x 10-12 /l, ...
... provides a comprehensive microarray service for ... embedded within non-coding RNAs (ncRNAs) using ... probe design, which enables highly sensitive ... RNAs (1). This comprehensive service includes ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... For knockdown of all human, mouse, ... , Genomewide, predesigned siRNAs for ... , Ready-to-use, convenient matching solutions ... Cost-effective RNAi and downstream ...
Biology Products: